@article{3ff919b6776447a3835949b0377e252b,
title = "Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for {"}intermediate risk{"}",
abstract = "Recent primary prevention guidelines issued in Canada endorse the use of statin therapy among individuals at {"}intermediate risk{"} who have elevated levels of high-sensitivity C-reactive protein (hsCRP). However, trial data directly addressing whether this recommendation defines a patient population in which statin therapy is effective have not previously been published.",
keywords = "Aged, C-Reactive Protein, Canada, Cardiovascular Diseases, Cholesterol, LDL, Evidence-Based Medicine, Female, Fluorobenzenes, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Middle Aged, Practice Guidelines as Topic, Primary Prevention, Pyrimidines, Risk, Sulfonamides, Treatment Outcome",
author = "Ridker, {Paul M} and Macfadyen, {Jean G} and Nordestgaard, {B{\o}rge G} and Wolfgang Koenig and Kastelein, {John J P} and Jacques Genest and Glynn, {Robert J}",
year = "2010",
month = sep,
doi = "10.1161/CIRCOUTCOMES.110.938118",
language = "English",
volume = "3",
pages = "447--52",
journal = "Circulation. Cardiovascular Quality and Outcomes",
issn = "1941-7713",
publisher = "Lippincott Williams and Wilkins",
number = "5",
}